Oct 26, 2026 07:01AM
Oct 26, 2026 07:00AM
Oct 6, 2026 04:02PM
Sep 30, 2026 04:06PM
Sep 30, 2026 07:47AM
Sep 30, 2026 07:45AM
Aug 11, 2026 04:02PM Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026 04:02PM
Jul 20, 2026 07:30AM
Jul 20, 2026 07:30AM
Jul 9, 2026 06:48AM
Jul 8, 2026 07:30AM
Jul 8, 2026 07:30AM
Jul 7, 2026 04:02PM Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 11, 2026 07:30AM
Jun 11, 2026 07:30AM
Jun 4, 2026 04:02PM
May 30, 2026 08:00AM
May 30, 2026 08:00AM
May 27, 2026 08:00AM
May 12, 2026 04:02PM Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Apr 29, 2026 07:30AM
Apr 29, 2026 07:30AM
Apr 21, 2026 10:30AM
Apr 21, 2026 10:30AM
Mar 3, 2026 04:02PM
Feb 5, 2026 09:26AM
Dec 16, 2025 12:18PM Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Dec 16, 2025 07:20AM
Dec 15, 2025 07:00AM
Dec 15, 2025 07:00AM
Nov 17, 2025 07:08AM
Aug 6, 2025 04:05PM
Feb 11, 2025 08:30AM
Jan 13, 2025 08:00AM Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Oct 29, 2024 08:00AM
Oct 18, 2024 08:00AM
Jul 25, 2024 08:00AM
Mar 26, 2024 08:00AM
Feb 20, 2024 08:00AM
Feb 6, 2024 08:00AM
Feb 6, 2024 08:00AM Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Nov 9, 2023 08:00AM
Oct 3, 2023 08:05AM
Oct 3, 2023 08:00AM
Jun 29, 2023 09:01AM
Jun 29, 2023 09:00AM
May 23, 2023 04:07PM
May 23, 2023 04:05PM Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 5, 2023 08:00AM

335,322 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All